The input parameters to the model.

<div><p>Objective</p><p>This study aims to conduct a cost-effectiveness analysis of tislelizumab in combination with platinum and etoposide compared to the standard treatment of etoposide and platinum as first-line therapy for extensive-stage small cell lung cancer(ES-SCLC) f...

Full description

Saved in:

Bibliographic Details
Main Author:	Zhiwei Zheng (736521) (author)
Other Authors:	Huide Zhu (2643967) (author), Ling Fang (139421) (author)
Published:	2025
Subjects:	Medicine Pharmacology Biotechnology Cancer Science Policy developed utilizing data total expenses amounted effective treatment option various cost components sensitivity analyses confirmed 312 trial demonstrates partitioned survival model 21 qaly compared tislelizumab group experienced effectiveness analysis based 79 per qaly tislelizumab plus platinum chinese wtp threshold sensitivity analyses 312 trial tislelizumab group total cost model accounted overall survival free survival effectiveness analysis chemotherapy group analysis employed treatment arms standard treatment line treatment xlink "> study aims standard chemotherapy namely progression line therapy incremental cost findings across effectiveness ratio economic outcomes drug therapy disease progression disease progresses albeit incurring adverse events adjusted life additional cost accurately simulate
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

The input parameters to the model.

Similar Items